Humanized antibodies for CD3
The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
1. An antibody or antibody fragment specific for cluster of differentiation 3 (CD3), wherein said antibody or antibody fragment specifically binds to human CD3 and to non-human primate CD3, wherein said antibody or antibody fragment comprises a heavy chain variable domain of SEQ ID NO: 7 and a light chain variable domain of SEQ ID NO: 17.
2. The antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment specifically binds to human CD3 epsilon and cynomolgus monkey CD3 epsilon.
3. The antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is a humanized or chimeric antibody or antibody fragment thereof.
4. The antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is an isolated antibody or antibody fragment.
5. The antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment.
6. The antibody or antibody fragment according to claim 1 , wherein the antibody is a full-length IgG.
7. The antibody or antibody fragment according to claim 6 , wherein the full-length IgG is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
8. The antibody or antibody fragment according to claim 6 , wherein the full-length IgG comprises an Fc region that has reduced effector function relative to that of a wild type Fc-receptor or an Fc region, wherein in at least 5 amino acids in the positions corresponding to positions L234, L235, D237, N330, P331 in a human IgG1 heavy chain, are mutated to A, E, A, S, and S, respectively.
9. The antibody or antibody fragment according to claim 1 , wherein the antibody fragment is a Fab fragment.
10. The antibody or antibody fragment according to claim 1 , wherein the antibody is a single chain antibody.
11. A pharmaceutical composition comprising the antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier or excipient.
12. A bispecific antibody comprising a first antigen binding domain of an antibody or antibody fragment according to claim 1 , and a second antigen binding domain which binds a different target antigen than said first antigen binding region.
13. The bispecific antibody according claim 12 , wherein the second binding region specifically binds a cell surface target antigen.
14. The bispecific antibody according to claim 12 , wherein said bispecific antibody comprises an Fc region that has reduced effector function relative to that of a wild type Fc-receptor or an Fc region wherein in at least 5 amino acids in the positions corresponding to positions L234, L235, D237, N330, P331 in a human IgG1 heavy chain, are mutated to A, E, A, S, and S, respectively.
15. A method for treating or delaying progression of cancer in a subject in need thereof, said method comprising administering to the subject a bispecific antibody of claim 12 wherein the second antigen binding domain binds a tumor antigen.